"Least burdensome" premarket review
This article was originally published in The Gray Sheet
Jan. 4 meeting between FDA and industry reps will include discussion of the FDA Modernization Act's mandate that the agency require the least burdensome review of premarket submissions ("The Gray Sheet" Dec. 14, p. 3). The meeting will take place from 1:00-4:00 p.m. at CDRH's Corporate Building. Those interested in attending should contact FDA's Cathy Hobbs at 301/594-2022
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.